Skip to main content
. 2020 Oct 31;32(5):580–595. doi: 10.21147/j.issn.1000-9604.2020.05.03

2. Comparison of clinico-pathological data between different histological grades of TNBC.

Variables n (%) P n (%) P
LG-cTNBC (n=85) HG-cTNBC (n=344) LG-TNBC (n=172) HG-TNBC (n=410)
TNBC, triple negative breast cancer; cTNBC, conventional type of triple negative breast cancer; LG, low grade; HG, high grade; DCIS, ductal carcinomain situ; TIL, tumor infiltrating lymphocytes; *, categorical variables were analyzed by Chi-squared test or Fisher’s exact test, and continuous data were analyzed using the Student’st-test.
Age (year) [median (range)] 55 (24−93) 53 (24−92) 0.096 59 (24−93) 53 (24−92) <0.001
DCIS
 Low 5 (14.3) 5 (4.2) <0.001 18 (20.0) 5 (3.6) <0.001
 Middle 24 (68.6) 54 (45.0) 59 (65.6) 64 (45.7)
 High 6 (17.1) 61 (50.8) 13 (14.4) 71 (50.7)
TILs
 Little 9 (32.1) 50 (28.2) 0.656 13 (26.5) 56 (27.5) 0.264
 Middle 6 (21.4) 29 (16.4) 13 (26.5) 34 (16.7)
 Large 13 (46.4) 98 (55.4) 23 (46.9) 114 (55.9)
HER2
 0 35 (41.7) 169 (49.3) 0.366 59 (34.7) 207 (50.6) <0.001
 1+ 32 (38.1) 122 (35.6) 67 (39.4) 144 (35.2)
 2+ 17 (20.2) 52 (15.2) 44 (25.9) 58 (14.2)
AR (%) [median (range)] 18 (0−90) 8 (0−90) 0.011 36 (0−90) 10 (0−90) <0.001
Neoadjuvant therapy 26 (31.7) 141 (42.7) 0.079 36 (21.8) 154 (38.9) <0.001
Tumor regression score
 G1 1 (3.7) 26 (18.7) 0.158* 4 (11.1) 28 (18.5) 0.164*
 G2 1 (3.7) 17 (12.2) 1 (2.8) 20 (13.2)
 G3 11 (40.7) 38 (27.3) 13 (36.1) 41 (27.2)
 G4 5 (18.5) 19 (13.7) 9 (25.0) 22 (14.6)
 G5 9 (33.3) 39 (28.1) 9 (25.0) 40 (26.5)
Tumor size (cm) [median
(range)]
1.90 (0.15−8.00) 2.32 (0.20−14.00) 0.133 1.96 (0.15−8.00) 2.42 (0.20−14.00) 0.005
Grade
 1 1 (1.2) 0 (0) <0.001* 23 (13.9) 0 (0) <0.001*
 2 80 (98.8) 0 (0) 143 (86.1) 0 (0)
 3 0 (0) 344 (100) 0 (0) 410 (100)
Score [median (range)] 7 (5−7) 8 (8−9) <0.001 6 (3−7) 8 (8−9) <0.001
Duct formation
 1 0 (0) 0 (0) <0.001* 3 (1.8) 0 (0) <0.001*
 2 12 (15.4) 0 (0) 30 (18.4) 0 (0)
 3 66 (84.6) 341 (100) 130 (79.8) 406 (100)
Nuclear grade
 1 1 (1.3) 0 (0) <0.001* 9 (5.5) 0 (0) <0.001*
 2 71 (91.0) 162 (47.5) 141 (86.5) 188 (46.3)
 3 6 (7.7) 179 (52.5) 13 (8.0) 218 (53.7)
Mitotic activity
 1 29 (37.2) 0 (0) <0.001* 88 (54.0) 0 (0) <0.001*
 2 44 (56.4) 20 (5.9) 69 (42.3) 30 (7.4)
 3 5 (6.4) 321 (94.1) 6 (3.7) 376 (92.6)
Mitotic count [median (range)] 9 (0−60) 28 (2−100) <0.001 7 (0−60) 27 (2−100) <0.001
Ki67 (%) [median (range)] 47 (8−95) 74(0−95) <0.001 36 (2−95) 72 (0−95) <0.001
Sentinel lymph node
metastasis
12 (30.8) 40 (21.5) 0.216 24 (27.3) 46 (20.8) 0.231
Lymph node metastasis 20 (52.6) 72 (48.3) 0.717 39 (53.4) 86 (48.6) 0.578
TNM
 1 19 (36.5) 86 (38.1) 0.002* 46 (38.3) 101 (36.2) 0.025
 2 20 (38.5) 87 (38.5) 49 (40.8) 105 (37.6)
 3 6 (11.5) 3 (1.3) 11 (9.2) 11 (3.9)
 4 7 (13.5) 50 (22.1) 14 (11.7) 62 (22.2)
Prognosis stage
 1 0 (0) 0 (0) 0.341* 1 (0.8) 0 (0) 0.038*
 2 19 (36.5) 87 (38.7) 52 (43.3) 102 (36.7)
 3 26 (50.0) 88 (39.1) 53 (44.2) 114 (41.0)
 4 7 (13.5) 50 (22.2) 14 (11.7) 62 (22.3)
T
 1 34 (65.4) 124 (55.1) 0.304 73 (60.8) 146 (52.5) 0.255*
 2 15 (28.8) 85 (37.8) 42 (35.0) 108 (38.8)
 3 3 (5.8) 9 (4.0) 4 (3.3) 15 (5.4)
 4 0 (0) 7 (3.1) 1 (0.8) 9 (3.2)
N
 0 27 (52.9) 149 (66.8) 0.153* 73 (61.3) 182 (65.9) 0.806*
 1 19 (37.3) 64 (28.7) 37 (31.1) 77 (27.9)
 2 1 (2.0) 4 (1.8) 3 (2.5) 7 (2.5)
 3 4 (7.8) 6 (2.7) 6 (5.0) 10 (3.6)
M
 0 46 (86.8) 176 (75.5) 0.099 106 (86.2) 217 (75.6) 0.018
 1 7 (13.2) 57 (24.5) 17 (13.8) 70 (24.4)